title: Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.
abstract: Preeclampsia (PE) is a multi-system disorder of human pregnancy, whose etiology remains poorly understood. Preeclamptic women are known to have an increased hypercoagulable state that result in excess fibrin deposition in several organs, which compromises their function. Tissue factor (TF) is the main physiological initiator of blood coagulation and its activity is regulated by a specific inhibitor known as Tissue factor pathway inhibitor (TFPI). Based on the important role of TF and TFPI in hemostasis, we hypothesize that their levels may change in the severe PE contributing to exacerbate hypercoagulable state. Some studies have assessed the balance between TF and TFPI in preeclamptic women, but results are inconsistent. Therefore, the aim of this study was to examine these inconsistencies and to assess TF and TFPI plasma levels in three groups of age matched women; pregnant with severe PE (n = 60), normotensive pregnant (n = 50) and normotensive non-pregnant women (n = 50). There was not significantly different among the three groups for TF plasma levels; severe PE women: 338.4 pg/mL (248.1-457.6), normotensive pregnant women: 301.5 pg/mL (216.4-442.9) and normotensive non-pregnant women 393 pg/mL (310.3-522.9). TFPI plasma levels were higher in severe PE comparing to normotensive pregnant women and normotensive non-pregnant women, 115.8 ng/mL (75-149.8); 80.3 ng/mL (59.6-99.7) and 74.5 ng/mL (47.1-98.0), respectively No difference was found between normotensive pregnant women and normotensive non-pregnant women. As for gestational age, a significant difference in TFPI levels was found between severe PE and normotensive pregnant women up to the 33rd week of pregnancy (p = 0.001), and severe PE and non-pregnant women up to the 34th (p = 0.01). In summary, our results indicated that TF plasma levels did not vary in the studied groups, while TFPI plasma levels were significantly increased in severe PE compared to normotensive pregnant and normotensive non-pregnant women. So, our data do not explain the exacerbated hypercoagulability state observed in severe PE. Further studies evaluating genes expression, TF activity and antigen, total and free TFPI and TFPI-2, both in plasma and obstetric tissues, throughout the pregnancy in PE (mild and severe forms) are required.
authors.affiliation: Clinical and Toxicological Department, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Gabinete 4104B3, Avenida Antônio Carlos, 6627 - Campus Pampulha, Belo Horizonte, MG 31270-901, Brazil. lacago@hotmail.com
authors.forename: Lara Carvalho
authors.initials: LC
authors.lastname: Godoi
authors.forename: Karina Braga
authors.initials: KB
authors.lastname: Gomes
authors.forename: Patrícia Nessralla
authors.initials: PN
authors.lastname: Alpoim
authors.forename: Maria das Graças
authors.initials: Md
authors.lastname: Carvalho
authors.forename: Bashir A
authors.initials: BA
authors.lastname: Lwaleed
authors.forename: Luci Maria
authors.initials: LM
authors.lastname: Sant'Ana Dusse
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood* / Q000503:physiopathology; D011247:Pregnancy; D011263:Pregnancy Trimester, Third / Q000097:blood*; D012720:Severity of Illness Index; D013925:Thromboplastin / Q000378:metabolism*
chemical_list: D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin